The global cancer biologics market size will grow by USD 40.38 billion during 2019-2023. This report offers an analysis of the market based on product (monoclonal antibodies, vaccines, cell and gene therapy, and others). The cancer biologics market research report further presents in-depth insights on the growth prospects of the market across Asia, Europe, North America, and ROW. The report analyzes the market’s competitive landscape and offers information on several companies including Amgen Inc., Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche Ltd, and Merck & Co., Inc.

To identify growth opportunities in the cancer biologics market, the market has been segmented into regions that are growing faster than the overall market. These regions have been pitted against regions that have a slower growth rate than the global market in 2018-2023. Asia and North America will grow faster than the overall market. The growth of Europe and ROW will be slower than the global market.

Below are some of the key findings from this cancer biologics market analysis report

See the complete table of contents and list of exhibits, as well as selected illustrations and example pages from this report.

Get a FREE sample now!  

Global Cancer Biologics Industry Overview

There is an increase in the development of cancer treating biologic molecules because of the growing investments by emerging and established players. Most of these biologic molecules are in the late stages of development and they have various therapeutic advantages and better safety and efficacy to treat cancer. Stem cell therapy, targeted therapy, gene therapy, antisense and RNAi therapy, and cancer vaccines are some of the different classes of innovative biologics. Regulatory agencies are also granting approvals for these new biologics to treat patients with metastatic SCLC and address the global burden of cancer. With new drug approvals and the presence of a robust pipeline, the cancer biologics market will grow at a rapid rate in the coming years.

The increased use of predictive biomarkers will also contribute to the growth of the cancer biologics market, which will register a CAGR of over 11% during the forecast period. Healthcare agencies and manufacturers are helping physicians to decide treatments for their patients by utilizing physiological biomarkers for predicting the performance. Predictive biomarkers study tumor growth in patients by analyzing the major etiological factors as the cancer etiology differs from patient to patient. These biomarkers not only aid in the early detection of cancer but also help in deciding the cost-effective treatment regimens, especially for the biologics based on gene therapy.